Investor Presentaiton

Investor presentation Full year 2018 Slide 6 Sales growth is primarily driven by 18% growth in GLP-1 sales, while global insulin sales are broadly unchanged 2018 reported sales split and local currency growth for NAO and IO 2018 added sales and local currency growth for NAO and IO Insulin Obesity DKK GLP-1 Biopharm Other diabetes care Local currency growth International Operations North America Operations Group local currency growth billion DKK billion Therapy areas 60 6 3% 7% 5% -1% 18% 60% -1% 5 50- 4 40 International Operations regions 14% 3 7% 20 30 3% 20 2 19% 1 5% 3% 131% 39% 3% 11% 8% 0 -6% 10 -2% 29% -1 -7% 0 -2 NAO IO Region Region Region Region Region Europe AAMEO China J&K LATAM Total¹ Insulin GLP-1 Obesity Biopharm NAO: North America Operations; IO: International Operations; LATAM: Latin America; AAMEO: Africa, Asia, Middle East & Oceania; J&K: Japan & Korea 1 "Other diabetes care" is included in Total novo nordisk

View entire presentation